Journal of Clinical Oncology

Vol. 43, Issue 1 Issue 1 2025
20
Articles

Articles in this Issue

On the Nose: Reducing Nasopharyngeal Cancer–Related Mortality Using Risk-Based Epstein-Barr Virus Serology Screening

Philip E. Castle, Paul K.J. Han Jan 01, 2025 pp. 1-3 10.1200/jco-24-01605

Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double Standard?

Humaid O. Al-Shamsi, Nadia Abdelwahed, Kefah Mokbel Jan 01, 2025 pp. 109-111 10.1200/jco.24.01186

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

Christoph Röllig, Björn Steffen, Christoph Schliemann et al. Jan 01, 2025 pp. 65-74 10.1200/jco.24.00235

PURPOSE To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a o...

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

Matthew D. Galsky, Johannes Alfred Witjes, Jürgen E. Gschwend et al. Jan 01, 2025 pp. 15-21 10.1200/jco.24.00340

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or sec...

How We Monitor Cardiac Health in Breast Cancer Survivors

Suparna C. Clasen, Meagan E. Miller Jan 01, 2025 pp. 4-9 10.1200/jco.24.00757

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagn...

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Michael J. Thirman, C. Michel Zwaan, Neerav Shukla et al. Jan 01, 2025 pp. 75-84 10.1200/jco.24.00826

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a...

Advances in Vulvar Cancer Biology and Management

Rania Chehade, Katarzyna J. Jerzak, Farideh Tavanger et al. Jan 01, 2025 pp. 89-100 10.1200/jco.24.01071

PURPOSE Vulvar squamous cell carcinoma (VSCC), a rare gynecologic malignancy, has been rising in incidence. Molecular classification on the basis of human papilloma virus (HPV) and tumor p...

Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors

Geoffrey Bostany, Yanjun Chen, Liton Francisco et al. Jan 01, 2025 pp. 32-45 10.1200/jco.23.01779

PURPOSE Cardiac dysfunction is the leading cause of mortality among 10-year breast cancer survivors. Limited information regarding long-term risks of cardiac dysfunction after cardiotoxic...

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

Humera Khurshid, Nofisat Ismaila, Jessica Bian et al. Jan 01, 2025 pp. 101-105 10.1200/jco-24-02245

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an e...

Underrated But Significant Risk Factors of Osteoradionecrosis of the Jaw in Patients With Head and Neck Cancer

Erkan Topkan, Efsun Somay, Sibel Bascil et al. Jan 01, 2025 pp. 106-107 10.1200/jco.24.01020

Reply to E. Topkan et al

Erin E. Watson, Katrina Hueniken, Junhyung Lee et al. Jan 01, 2025 pp. 107-109 10.1200/jco-24-01520

Revumenib Revises the Treatment Landscape for <i>KMT2A</i> -r Leukemia

Emily B. Heikamp, Scott A. Armstrong Jan 01, 2025 pp. 85-88 10.1200/jco-24-01265

Reply to H.O. Al-Shamsi et al

Brooke E. Wilson, Kristin Wright, Christopher M. Booth Jan 01, 2025 pp. 111-112 10.1200/jco-24-01689

Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial

Wen-Jie Chen, Xia Yu, Yu-Qiang Lu et al. Jan 01, 2025 pp. 22-31 10.1200/jco.23.01296

PURPOSE Screening for nasopharyngeal carcinoma (NPC) has shown an improvement in early detection and survival rates of NPC in endemic regions. It is critical to evaluate whether NP...

How Racialized Approaches to Opioid Use Disorder and Opioid Misuse Management Hamper Pharmacoequity for Cancer Pain

Katie Fitzgerald Jones, Kevin T. Liou, Rebecca L. Ashare et al. Jan 01, 2025 pp. 10-14 10.1200/jco.24.00705

@JCO_ASCO paper focuses on racialized approaches to OUD and opioid misuse as underappreciated drivers of disparities in cancer and recs a path forward.

Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial

Jan 01, 2025 pp. 113-113 10.1200/jco-24-02458

Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Jan 01, 2025 pp. 114-114 10.1200/jco-24-02470

Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery

Nina A. Bickell, Ann B. Nattinger, Emily L. McGinley et al. Jan 01, 2025 pp. 57-64 10.1200/jco.23.02638

PURPOSE Reimbursement strategies to regionalize care can be effective for improving patient outcomes but may adversely affect access to care. We sought to determine the effect on travel di...

Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Jan 01, 2025 pp. 113-113 10.1200/jco-24-02469

Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD

Heidi D. Klepin, Simon C. Lee, Brian J. Wells et al. Jan 01, 2025 pp. 46-56 10.1200/jco.24.00342

PURPOSE Guidelines recommend cardiovascular (CV) risk assessment and counseling for cancer survivors. This study evaluated the automated heart-health assessment (AH-HA) clinical decision s...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page